论文部分内容阅读
近年随着肾素-血管紧张素-醛固酮(renin-angiotensin-aldosterone,RAA)系统的研究进展,抗 RAA 系统药物相继问世。此类药物主要包括心得安等β阻滞剂、血管紧张素(A)Ⅱ竞争性抑制剂肌丙抗增压素(saralasin)、血管紧张素转换酶(angiotensin convertingenzyme,ACE)抑制剂如壬肽抗压素(teprotide)及甲巯丙脯酸(captopril)。其中心得安等β阻滞剂已应用于临床治疗高血压,但疗效尚不甚满意。如对原发性高血压患者约50％可有明显降压作用;肌丙抗增压素静脉输注仅对15～20％原发性高血压有效。而且低肾素型病人用药后有可能发生升压现象,临床治疗价值不大。壬肽抗压索虽然降压作用较强,但只能静脉给药,临床应用受限。1977年动物实验首次证明合成的甲巯丙脯酸有显著降压作用。以后的动物实验及临床
In recent years, with the progress of renin-angiotensin-aldosterone (RAA) system, anti-RAA system drugs have come out one after another. Such drugs include prednisone beta blockers, angiotensin (angiotensin convertingenzyme, ACE) inhibitors such as nonane peptide (Ang Ⅱ), a competitive inhibitor of angiotensin (A) Teprotide and captopril. Its central beta and other beta blockers have been used in clinical treatment of hypertension, but the effect is not yet satisfactory. Such as about 50% of patients with essential hypertension can have significant antihypertensive effect; muscle C anti-vasopressin infusion only 15 to 20% of essential hypertension. And low-renin-type patients may increase the phenomenon after treatment, clinical treatment of little value. Nonane anti-stress cable, although a strong antihypertensive effect, but only intravenous administration, limited clinical applications. Animal experiments for the first time in 1977 showed that the synthetic captopril has a significant antihypertensive effect. After the animal experiments and clinical